Comparative study of efficacy and safety of Yahom-Navakot remedy plus Levofloxacin vs Levofloxacin alone in prevention of nosocomial infection in post-cardiac arrest patients treated by targeted temperature management: A randomized, double blinded, placebo controlled trial

Comparative study of efficacy and safety of Yahom-Navakot remedy plus Levofloxacin vs Levofloxacin alone in prevention of nosocomial infection in post-cardiac arrest patients treated by targeted temperature management: A randomized, double blinded, p

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200430004

Enrollment

Registered

2020-04-30

Start date

2020-04-02

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-Cardiac Arrest Patients Targeted Temperature Management, Nosocomial Infection,Levofloxacin, Yahom-Navakot remedy and Post-cardiac arrest

Interventions

1. Active Yahom&#45

Navakot remedy 2. Active levofloxacin ,1. Placebo Yahom&#45

Navakot remedy 2. Placebo levofloxacin

Active Comparator Drug,Active Comparator Drug,Placebo Comparator Drug

Yahom&#45

Navakot remedy plus Levofloxacin ,Levofloxacin,Placebo

Eligibility

Sex/Gender

All

Age

20 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Ventricular fibrillation or pulseless ventricular tachycardia 2. Witnessed arrest 3. Glassgow Coma scale(GCS) < 8 4. Systolic Blood Pressure > 90 mmHg 5. Receive Targeted Temperature Management 6. Male and female with age 20-90 year old

Exclusion criteria

Exclusion criteria: 1. Known allergy to Yahom-Navakot remedy or levofloxacin 2. Terminal illness 3. Pregnancy and lactation 4. Known infection with antibiotic usage within 1 week 5. abnormal clotting with unable to recovery 6. GI bleeding 7. unable to have NG-tube feeding or GI malabsorption

Design outcomes

Primary

Measure	Time frame
Infection rate day 1, day 3 and day 7 % of infection	—

Secondary

Measure	Time frame
Adverse event day 1, day 3 and day 7 frequency and %	—

Countries

Thailand

Contacts

Public ContactSombat Muengtaweepongsa

Faculty of Medicine, Thammasat University

sombatm@hotmail.com6686 999 4208

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026